Matt Linley

Matt Linley
Dr Matt Linley is Senior Director for Analytics and Forecasting at Airfinity. At Airfinity he works with key stakeholders from governments, big pharma and biotech companies as well as NGOs and leads the forecasting on disease outcomes as well as modelling the health economics of disease management under different scenarios. He leads a multidisciplinary team of pharmacologists, epidemiologists, economists and data scientists in order to derive insights from large data that Airfinity have collected. He holds a PhD from the University of Cambridge, where he researched and modelled cellular interactions and bioactivity of medical materials.
Dr Matt Linley is Senior Director for Analytics and Forecasting at Airfinity. At Airfinity he works with key stakeholders from governments, big pharma and biotech companies as well as NGOs and leads the forecasting on disease outcomes as well as modelling the health economics of disease management under different scenarios. He leads a multidisciplinary team of pharmacologists, epidemiologists, economists and data scientists in order to derive insights from large data that Airfinity have collected. He holds a PhD from the University of Cambridge, where he researched and modelled cellular interactions and bioactivity of medical materials.

Articles: Matt Linley

Breakthrough Treatments Could Relegate RSV Seasons Like 2023 To History Books

Global / Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV), which has seen a major spike in cases this winter. Linley assesses the potential impact of some major new treatments for both infants and the…

See more